Alastair Thomson, chief data officer at the HHS sub-agency, announced his resignation in opposition to Health Secretary ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

The stop order came on Aug. 5, the same day Health Secretary Robert F. Kennedy Jr. terminated 22 mRNA vaccine projects under ...

The Annals of Internal Medicine ran a large-scale study in July, pointing to the lack of an association between childhood ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This whitepaper will show leaders how strategic insights and targeted outreach can turn ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Gray Delany's ouster comes days after Health Secretary Robert F. Kennedy Jr. controversially axed 22 mRNA vaccine contracts ...

Skysona can now only be used in patients with cerebral adrenoleukodystrophy who have no available treatment alternatives or ...

An interview with Philip Vanek, chief commercialization officer of the International Society for Cell & Gene Therapy (ISCT), ...

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some ...